Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Adcetris gives Pfizer its first post-Seagen surprise
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
MacroGenics muddies its key catalyst
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
